Literature Review: Hepatocellular Carcinoma Cell Imaging

5th March 2019
Hepatocellular carcinoma (HCC) is a common malignant cancer.  Glypican-3 (GPC3), a cellular membrane proteoglycan, is highly expressed in more than 70% of HCC patients and therefore may be an ideal biomarker for in vivo HCC diagnosis and imaging. Antibody reagents have limitations such as immunogenicity, easy degradation, and high cellular cytotoxicity effect in […]

Literature Review: Aptamers for analysis of rituximab and biosimilars

26th February 2019
Unlike chemically synthesised small molecule pharmaceuticals, biopharmaceuticals are a new generation of protein-based medicines. These biologics are usually protected by patents but as those patents expire the door is opened to biosimilar proteins which perform similarly to the original biologic. Small adjustments can affect the efficacy and stability of the biosimilar, so characterisation […]

Alternate Approach to Small Molecule Detection Verified by Multiple Assay Formats

The ELISA (enzyme-linked immunosorbent assay) is a plate-based method used to detect and quantify a variety of materials such as proteins, peptides, and small molecules. In general, the assay involves immobilization of the target (either directly or through a ‘capture reagent’), detection with a specific antibody or aptamer molecule, and quantification using a variety of […]

Aptamer Group February 2019

14th February 2019
This month:

Aptamers for therapeutic drug monitoring in plasma
Aptamer Group speaking at a premier aptamer conference
Interesting applications in portable quantitative aptasensors and  protease inhibitors

With lots of new data ongoing for multiple applications in the commercial and academic space, Aptamer Group would like to share with you information that may be of interest […]

Literature Review: Novel Aptamer Protease Inhibitors

13th February 2019
Serine proteases are enzymes that cleave peptide bonds in proteins, in which serine serves as the reactive amino acid at the enzyme’ active site. In humans, they are responsible for coordinating various physiological functions, including digestion, immune response, blood coagulation and reproduction (Hedstrom). The design and development of small molecule inhibitors of proteases have […]

Aptamers for Therapeutic Drug Monitoring in Plasma

5th February 2019
Aptamer Group recently collaborated with a commercial partner to develop aptamers to a variety of small molecule drugs and their active metabolites for biosensor based therapeutic drug monitoring.  Therapeutic drug monitoring (TDM) is the clinical practice of measuring drugs and their subsequent metabolites at designated intervals to understand concentration in a patient’s bloodstream […]

Literature Review: Portable Quantitative Malaria Aptasensor

30th January 2019

Malaria is a serious life-threatening disease, affecting a large section of the population mostly in tropical and subtropical low and middle income countries (Gallup and Sachs, 2001; World Malaria Report,2016). Currently, lateral flow based immuno-chromatographic tests are widely used for detection of malaria. However, these antibody based assays are usually non-quantitative in nature […]

Literature Review: Detecting glioblastoma biomarker aptamers from whole cell SELEX in body fluids

22nd January 2019
Glioma is an often invasive cancer displaying a heterogeneous cell population derived from transformed glial cells. To date there are limited trustworthy biomarkers for the detection and risk stratification of glioma. The objective of the present research was to select DNA aptamers to facilitate early diagnosis and effective therapy of glioma.

Aptamers were developed […]

  • Working in a lab at Aptamer Group

Aptamer Group January 2019

17th January 2019
This month:

Aptamer Group announces collaboration with AstraZeneca
Cancer Biomarker Capture and Elution by Cell Specific Aptamers
Laboratory and Office expansion
Interesting applications in glioblastoma and hepatocellular carcinoma (HCC) biomarker aptamers

With lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to share with […]

Cancer Biomarker Capture and Elution by Cell Specific Aptamers

15th January 2019

Aptamers have a great potential in cancer biomarker discovery via selection against cancer cells following counter selection against healthy cells. Aptamers were identified to bind to cancer specific biomarkers on cells and then subsequently isolated and analysed.

Prostate cancer cells were lysed and incubated with streptavidin magnetic beads pre-immobilized with a biotinylated single stranded […]